1. H. H. Moffet, “Sham Acupuncture May Be as Efficacious as True Acupuncture: A Systematic Review of Clinical Trials,” Journal of Alternative and Complementary Medicine 15, no. 3 (March 2009): 213–216, https://doi.org/10.1089/acm.2008.0356..
2. C. E. Kerr, I. Milne, and T. J. Kaptchuk, “William Cullen and a Missing Mind-Body Link in the Early History of Placebos,” Journal of the Royal Society of Medicine 101, no. 2 (February 2008): 89–92, https://doi.org/10.1258/jrsm.2007.071005.
3. A. Tinnermann, S. Geuter, C. Sprenger, J. Finsterbusch, and C. Buchel, “Interactions between Brain and Spinal Cord Mediate Value Effects in Nocebo Hyperalgesia,” Science 358, no. 6359 (October 6, 2017): 105–108, https://doi.org/10.1126/science.aan1221; S. Kam-Hansen, M. Jakubowski, J. M. Kelley, I. Kirsch, D. C. Hoaglin, T. J. Kaptchuk, and R. Burstein, “Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks,” Science Translational Medicine 6, no. 218 (January 8, 2014): 218ra5. https://doi.org/10.1126/scitranslmed.3006175; K. Faasse and L. R. Martin, “The Power of Labeling in Nocebo Effects,” International Review of Neurobiology 139 (2018): 379–406, https://doi.org/10.1016/bs.irn.2018.07.016.
4. N. Humphrey, “Great Expectations: The Evolutionary Psychology of Faith-Healing and the Placebo Response,” in Psychology at the Turn of the Millennium: Vol. 2: Social, Developmental, and Clinical Perspectives, ed. C. von Hofsten and L. Bäckman (Hove, UK: Psychology Press, 2002), 225–246; F. G. Miller, L. Colloca, and T. J. Kaptchuk, “The Placebo Effect: Illness and Interpersonal Healing,” Perspectives in Biology and Medicine 52, no. 4 (2009): 518–539, https://doi.org/10.1353/pbm.0.0115.
1. J. Haygarth, Of the Imagination, as a Cause and as a Cure of Disorders of the Body: Exemplified by Fictitious Tractors and Epidemical Convulsions (Bath, UK: R. Cruttwell, 1800).
2. C. Booth, “The Rod of Aesculapios: John Haygarth (1740–1827) and Perkins’ Metallic Tractors,” Journal of Medical Biography 13, no. 3 (August 2005): 155–161, https://doi.org/10.1177/096777200501300310.
3. C. E. Kerr, I. Milne, and T. J. Kaptchuk, “William Cullen and a Missing Mind-Body Link in the Early History of Placebos,” Journal of the Royal Society of Medicine 101, no. 2 (February 2008): 89–92, https://doi.org/10.1258/jrsm.2007.071005.
4. Haygarth, Of the Imagination, 2.
5. I. Donaldson, “Royal Commission on Animal Magnetism,” 2014, https://www.rcpe.ac.uk/sites/default/files/files/the_royal_commission_on_animal_-_translated_by_iml_donaldson_1.pdf.
6. B. Franklin, The Autobiography of Benjamin Franklin (New York: Simon and Schuster, 2004).
7. Haygarth, Of the Imagination.
8. J. H. Stewart, “Hypnosis in Contemporary Medicine,” Mayo Clinic Proceedings 80, no. 4 (April 2005): 511–524, https://doi.org/10.4065/80.4.511.
9. Stewart, “Hypnosis in Contemporary Medicine.”
10. I. Loudon, “A Brief History of Homeopathy,” Journal of the Royal Society of Medicine 99, no. 12 (2006): 607–610. doi:10.1258/jrsm.99.12.607.
11. J. Sliwinski and G. R. Elkins, “Enhancing Placebo Effects: Insights from Social Psychology,” American Journal of Clinical Hypnosis 55, no. 3 (January 2013): 236–248, https://doi.org/10.1080/00029157.2012.740434; M. Z. Teixeira, C. H. Guedes, P. V. Barreto, and M. A. Martins, “The Placebo Effect and Homeopathy,” Homeopathy 99, no. 2 (April 2010): 119–129, https://doi.org/10.1016/j.homp.2010.02.001.
12. S. Junod, “FDA and Clinical Drug Trials: A Short History,” US Food and Drug Administration, https://www.fda.gov/media/110437/download.
13. Records of the Lydia E. Pinkham Medicine Company, 1776–ca.1985 (inclusive), 1859–1968 (bulk), Schlesinger Library, Radcliffe Institute, Harvard Archives.
14. Richard Cabot, “Truth and Falsehood in Medicine,” Journal of the American Medical Association 40, no. 15 (1903): 994–994, https://doi.org/10.1001/jama.1903.02490150046006.
15. H. G. Wolff, E. F. Dubois, and H. Gold, “The Use of Placebos in Therapy,” New York State Journal of Medicine 46 (August 1, 1946): 1718–1727, https://www.ncbi.nlm.nih.gov/pubmed/20993884.
16. C. Carvalho, J. M. Caetano, L. Cunha, P. Rebouta, T. J. Kaptchuk, and I. Kirsch, “Open-Label Placebo Treatment in Chronic Low Back Pain: A Randomized Controlled Trial,” Pain 157, no. 12 (December 2016): 2766–2772, https://doi.org/10.1097/j.pain.0000000000000700.
17. D. Purves, G. J. Augustine, D. Fitzpatrick, et al., “Central Regulation of Pain Perception,” in Neuroscience, ed. D. Purves, G. J. Augustine, D. Fitzpatrick, L. C. Katz, A.-S. LaMantia, J. O. McNamara, and S. M. Williams, chap. 10 (Sunderland, MA: Sinauer Associates, 2001).
18. J. D. Levine, N. C. Gordon, and H. L. Fields, “The Mechanism of Placebo Analgesia,” Lancet 2, no. 8091 (September 23, 1978): 654–657, https://doi.org/10.1016/s0140-6736(78)92762-9.
19. P. Petrovic, E. Kalso, K. M. Petersson, and M. Ingvar, “Placebo and Opioid Analgesia—Imaging a Shared Neuronal Network,” Science 295, no. 5560 (March 1, 2002): 1737–1740, https://doi.org/10.1126/science.1067176; T. D. Wager, J. K. Rilling, E. E. Smith, A. Sokolik, K. L. Casey, R. J. Davidson, S. M. Kosslyn, et al., “Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain,” Science 303, no. 5661 (February 20, 2004): 1162–1167, https://doi.org/10.1126/science.1093065; H. S. Mayberg, J. A. Silva, S. K. Brannan, J. L. Tekell, R. K. Mahurin, S. McGinnis, and P. A. Jerabek, “The Functional Neuroanatomy of the Placebo Effect,” American Journal of Psychiatry 159, no. 5 (May 2002): 728–737, https://doi.org/10.1176/appi.ajp.159.5.728; R. de la Fuente-Fernandez, T. J. Ruth, V. Sossi, M. Schulzer, D. B. Calne, and A. J. Stoessl, “Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson’s Disease,” Science 293, no. 5532 (August 10, 2001): 1164–1166, https://doi.org/10.1126/science.1060937.
1. Hesam Dashti, personal communication, November 3, 2021.
2. P. I. Pavlov, “Conditioned Reflexes: An Investigation of the Physiological Activity of the Cerebral Cortex,” Annals of Neuroscience 17, no. 3 (July 2010): 136–141, https://doi.org/10.5214/ans.0972-7531.1017309.
3. R. J. Herrnstein, “Placebo Effect in the Rat,” Science 138, no. 3541 (November 9, 1962): 677–678, https://doi.org/10.1126/science.138.3541.677.
4. R. O. Pihl and J. Altman, “An Experimental Analysis of the Placebo Effect,” Journal of Clinical Pharmacology 11, no. 2 (March–April 1971): 91–95, https://doi.org/10.1177/009127007101100203.
5. J. M. Danion, S. Peretti, D. Grange, M. Bilik, J. L. Imbs, and L. Singer, “Effects of Chlorpromazine and Lorazepam on Explicit Memory, Repetition Priming and Cognitive Skill Learning in Healthy Volunteers,” Psychopharmacology 108, no. 3 (1992): 345–351, https://doi.org/10.1007/BF02245122.
6. J. Garcia, W. G. Hankins, J. H. Robinson, and J. L. Vogt, “Bait Shyness: Tests of CS-US Mediation,” Physiology and Behavior 8, no. 5 (May 1972): 807–810, https://doi.org/10.1016/0031-9384(72)90288-0.
7. R. Ader and N. Cohen, “Behaviorally Conditioned Immunosuppression,” Psychosomatic Medicine 37, no. 4 (July–August 1975): 333–340, https://www.ncbi.nlm.nih.gov/pubmed/1162023.
8. M. Hadamitzky, L. Luckemann, G. Pacheco-Lopez, and M. Schedlowski, “Pavlovian Conditioning of Immunological and Neuroendocrine Functions,” Physiological Reviews 100, no. 1 (January 1, 2020): 357–405, https://doi.org/10.1152/physrev.00033.2018.
9. A. Buske-Kirschbaum, C. Kirschbaum, H. Stierle, H. Lehnert, and D. Hellhammer, “Conditioned Increase of Natural Killer Cell Activity (NKCA) in Humans,” Psychosomatic Medicine 54, no. 2 (March–April 1992): 123–132, https://doi.org/10.1097/00006842-199203000-00001.
10. D. W. Giang, A. D. Goodman, R. B. Schiffer, D. H. Mattson, M. Petrie, N. Cohen, and R. Ader, “Conditioning of Cyclophosphamide-Induced Leukopenia in Humans,” Journal of Neuropsychiatry and Clinical Neurosciences 8, no. 2 (Spring 1996): 194–201, https://doi.org/10.1176/jnp.8.2.194.
11. L. Colloca, P. Enck, and D. DeGrazia, “Relieving Pain Using Dose-Extending Placebos: A Scoping Review,” Pain 157, no. 8 (August 2016): 1590–1598, https://doi.org/10.1097/j.pain.0000000000000566.
12. S. Stewart-Williams and J. Podd, “The Placebo Effect: Dissolving the Expectancy versus Conditioning Debate,” Psychological Bulletin 130, no. 2 (March 2004): 324–340, https://doi.org/10.1037/0033-2909.130.2.324.
13. V. S. Ramachandran and E. L. Altschuler, “The Use of Visual Feedback, in Particular Mirror Visual Feedback, in Restoring Brain Function,” Brain 132, no. 7 (July 2009): 1693–1710, https://doi.org/10.1093/brain/awp135.
14. J. P. Fisher, D. T. Hassan, and N. O’Connor, “Minerva,” British Medical Journal 7, no. 310 (1995): 70, https://www.bmj.com/content/310/6971/70.
15. N. Peiris, M. Blasini, T. Wright, and L. Colloca, “The Placebo Phenomenon: A Narrow Focus on Psychological Models,” Perspectives in Biology and Medicine 61, no. 3 (2018): 388–400, https://doi.org/10.1353/pbm.2018.0051.
16. I. Kirsch, “Response Expectancy and the Placebo Effect,” International Review of Neurobiology 138 (2018): 81–93, https://doi.org/10.1016/bs.irn.2018.01.003.
17. U. Bingel, V. Wanigasekera, K. Wiech, R. Ni Mhuircheartaigh, M. C. Lee, M. Ploner, and I. Tracey, “The Effect of Treatment Expectation on Drug Efficacy: Imaging the Analgesic Benefit of the Opioid Remifentanil,” Science Translational Medicine 3, no. 70 (February 16, 2011): 70ra14, https://doi.org/10.1126/scitranslmed.3001244.
18. S. B. Penick and S. Fisher, “Drug-Set Interaction: Psychological and Physiological Effects of Epinephrine under Differential Expectations,” Psychosomatic Medicine 27 (March–April 1965): 177–182, https://doi.org/10.1097/00006842-196503000-00010; S. B. Lyerly, S. Ross, A. D. Krugman, and D. J. Clyde, “Drugs and Placebos: The Effects of Instructions upon Performance and Mood under Amphetamine Sulphate and Chloral Hydrate,” Journal of Abnormal Psychology 68 (March 1964): 321–327, https://doi.org/10.1037/h0044351; A. J. Dinnerstein and J. Halm, “Modification of Placebo Effects by Means of Drugs: Effects of Aspirin and Placebos on Self-Rated Moods,” Journal of Abnormal Psychology 75, no. 3 (June 1970): 308–314, https://doi.org/10.1037/h0029313.
19. F. Benedetti, “Placebo and the New Physiology of the Doctor-Patient Relationship,” Physiological Reviews 93, no. 3 (July 2013): 1207–1246, https://doi.org/10.1152/physrev.00043.2012.
20. L. Colloca, L. Lopiano, M. Lanotte, and F. Benedetti, “Overt versus Covert Treatment for Pain, Anxiety, and Parkinson’s Disease,” Lancet Neurology 3, no. 11 (November 2004): 679–684, https://doi.org/10.1016/S1474-4422(04)00908-1.
21. S. Kam-Hansen, M. Jakubowski, J. M. Kelley, I. Kirsch, D. C. Hoaglin, T. J. Kaptchuk, and R. Burstein, “Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks,” Science Translational Medicine 6, no. 218 (January 8, 2014): 218ra5, https://doi.org/10.1126/scitranslmed.3006175.
22. R. L. Waber, B. Shiv, Z. Carmon, and D. Ariely, “Commercial Features of Placebo and Therapeutic Efficacy,” Journal of the American Medical Association 299, no. 9 (March 5, 2008): 1016–1017, https://doi.org/10.1001/jama.299.9.1016; A. J. Espay, M. M. Norris, J. C. Eliassen, A. Dwivedi, M. S. Smith, C. Banks, J. B. Allendorfer, et al., “Placebo Effect of Medication Cost in Parkinson Disease: A Randomized Double-Blind Study,” Neurology 84, no. 8 (February 24, 2015): 794–802, https://doi.org/10.1212/WNL.0000000000001282.
23. K. Faasse, T. Cundy, G. Gamble, and K. J. Petrie, “The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects,” Psychosomatic Medicine 75, no. 1 (January 2013): 90–96, https://doi.org/10.1097/PSY.0b013e3182738826.
24. L. Colloca and F. Benedetti, “Placebo Analgesia Induced by Social Observational Learning,” Pain 144, no. 1–2 (July 2009): 28–34, https://doi.org/10.1016/j.pain.2009.01.033.
25. R. A. Wise, S. J. Bartlett, E. D. Brown, M. Castro, R. Cohen, J. T. Holbrook, C. G. Irvin, et al., “Randomized Trial of the Effect of Drug Presentation on Asthma Outcomes: The American Lung Association Asthma Clinical Research Centers,” Journal of Allergy and Clinical Immunology 124, no. 3 (September 2009): 436–444, https://doi.org/10.1016/j.jaci.2009.05.041.
26. K. R. Sepucha, L. H. Simmons, M. J. Barry, S. Edgman-Levitan, A. M. Licurse, and S. K. Chaguturu, “Ten Years, Forty Decision Aids, and Thousands of Patient Uses: Shared Decision Making at Massachusetts General Hospital,” Health Affairs 35, no. 4 (April 2016): 630–636, https://doi.org/10.1377/hlthaff.2015.1376.
1. L. Colloca, D. S. Pine, M. Ernst, F. G. Miller, and C. Grillon, “Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized Trial,” Biological Psychiatry 79, no. 10 (May 15, 2016): 794–802, https://doi.org/10.1016/j.biopsych.2015.07.019.
2. R. Melzack, “Evolution of the Neuromatrix Theory of Pain. The Prithvi Raj Lecture: Presented at the Third World Congress of World Institute of Pain, Barcelona 2004,” Pain Practice 5, no. 2 (June 2005): 85–94, https://doi.org/10.1111/j.1533-2500.2005.05203.x.
3. L. Colloca, Neurobiology of the Placebo Effect, Part I (Cambridge, MA: Academic Press, 2018).
4. B. Franklin, The Autobiography of Benjamin Franklin. (New York: Simon and Schuster, 2004).
5. P. Petrovic, E. Kalso, K. M. Petersson, and M. Ingvar, “Placebo and Opioid Analgesia—Imaging a Shared Neuronal Network,” Science 295, no. 5560 (March 1, 2002): 1737–1740, https://doi.org/10.1126/science.1067176; D. J. Scott, C. S. Stohler, C. M. Egnatuk, H. Wang, R. A. Koeppe, and J. K. Zubieta, “Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses,” Archives of General Psychiatry 65, no. 2 (February 2008): 220–231, https://doi.org/10.1001/archgenpsychiatry.2007.34; T. D. Wager, D. J. Scott, and J. K. Zubieta, “Placebo Effects on Human Mu-Opioid Activity during Pain,” Proceedings of the National Academy of Sciences of the United States of America 104, no. 26 (June 26, 2007): 11056–11061, https://doi.org/10.1073/pnas.0702413104; J. K. Zubieta, J. A. Bueller, L. R. Jackson, D. J. Scott, Y. Xu, R. A. Koeppe, T. E. Nichols, and C. S. Stohler, “Placebo Effects Mediated by Endogenous Opioid Activity on Mu-Opioid Receptors,” Journal of Neuroscience 25, no. 34 (August 24, 2005): 7754–7762, https://doi.org/10.1523/JNEUROSCI.0439-05.2005.
6. J. D. Levine, N. C. Gordon, and H. L. Fields, “The Mechanism of Placebo Analgesia,” Lancet 2, no. 8091 (September 23, 1978): 654–657, https://doi.org/10.1016/s0140-6736(78)92762-9.
7. M. Amanzio and F. Benedetti, “Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems,” Journal of Neuroscience 19, no. 1 (January 1 1999): 484–494, https://www.ncbi.nlm.nih.gov/pubmed/9870976.
8. Petrovic, Kalso, Petersson, and Ingvar, “Placebo and Opioid Analgesia.”
9. F. Eippert, U. Bingel, E. D. Schoell, J. Yacubian, R. Klinger, J. Lorenz, and C. Buchel, “Activation of the Opioidergic Descending Pain Control System Underlies Placebo Analgesia,” Neuron 63, no. 4 (August 27, 2009): 533–543, https://doi.org/10.1016/j.neuron.2009.07.014.
10. S. Geuter, L. Koban, and T. D. Wager, “The Cognitive Neuroscience of Placebo Effects: Concepts, Predictions, and Physiology,” Annual Review of Neuroscience 40 (July 25, 2017): 167–188, https://doi.org/10.1146/annurev-neuro-072116-031132.
11. M. Lopez-Sola, S. Geuter, L. Koban, J. A. Coan, and T. D. Wager, “Brain Mechanisms of Social Touch-Induced Analgesia in Females,” Pain 160, no. 9 (September 2019): 2072–2085, https://doi.org/10.1097/j.pain.0000000000001599; M. C. Reddan, H. Young, J. Falkner, M. Lopez-Sola, and T. D. Wager, “Touch and Social Support Influence Interpersonal Synchrony and Pain,” Social Cognitive and Affective Neuroscience 15, no. 10 (November 10, 2020): 1064–1075, https://doi.org/10.1093/scan/nsaa048.
12. T. D. Wager and L. Y. Atlas, “The Neuroscience of Placebo Effects: Connecting Context, Learning and Health,” Nature Reviews Neuroscience 16, no. 7 (July 2015): 403–418, https://doi.org/10.1038/nrn3976.
13. H. L. Fields, “Pain Modulation: Expectation, Opioid Analgesia and Virtual Pain,” Progress in Brain Research 122 (2000): 245–253, https://doi.org/10.1016/s0079-6123(08)62143-3.
14. G. Westheimer, “Was Helmholtz a Bayesian?,” Perception 37, no. 5 (2008): 642–650, https://doi.org/10.1068/p5973.
15. K. Friston, J. Kilner, and L. Harrison, “A Free Energy Principle for the Brain,” Journal of Physiology (Paris) 100, no. 1–3 (July–September 2006): 70–87, https://doi.org/10.1016/j.jphysparis.2006.10.001.
16. A. Grahl, S. Onat, and C. Buchel, . “The Periaqueductal Gray and Bayesian Integration in Placebo Analgesia,”.” El eLife 7 (Mar (March 20, 2018), . https://doi.org/10.7554/eLife.32930.
17. C. G. Goetz, J. Wuu, M. P. McDermott, C. H. Adler, S. Fahn, C. R. Freed, R. A. Hauser, et al., “Placebo Response in Parkinson’s Disease: Comparisons among 11 Trials Covering Medical and Surgical Interventions,” Movement Disorders 23, no. 5 (April 15, 2008): 690–699, https://doi.org/10.1002/mds.21894.
18. R. de la Fuente-Fernandez, T. J. Ruth, V. Sossi, M. Schulzer, D. B. Calne, and A. J. Stoessl, “Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson’s Disease,” Science 293, no. 5532 (August 10, 2001): 1164–1166, https://doi.org/10.1126/science.1060937; R. de la Fuente-Fernandez, A. G. Phillips, M. Zamburlini, V. Sossi, D. B. Calne, T. J. Ruth, and A. J. Stoessl, “Dopamine Release in Human Ventral Striatum and Expectation of Reward,” Behavioural Brain Research 136, no. 2 (November 15, 2002): 359–363, https://doi.org/10.1016/s0166-4328(02)00130-4.
19. Wager and Atlas, “The Neuroscience of Placebo Effects.”
20. A. Khan and W. A. Brown, “Antidepressants versus Placebo in Major Depression: An Overview,” World Psychiatry 14, no. 3 (October 2015): 294–300, https://doi.org/10.1002/wps.20241.
21. H. S. Mayberg, J. A. Silva, S. K. Brannan, J. L. Tekell, R. K. Mahurin, S. McGinnis, and P. A. Jerabek, “The Functional Neuroanatomy of the Placebo Effect,” American Journal of Psychiatry 159, no. 5 (May 2002): 728–737, https://doi.org/10.1176/appi.ajp.159.5.728.
22. M. Pecina, A. S. Bohnert, M. Sikora, E. T. Avery, S. A. Langenecker, B. J. Mickey, and J. K. Zubieta, “Association between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression,” JAMA Psychiatry 72, no. 11 (November 2015): 1087–1094, https://doi.org/10.1001/jamapsychiatry.2015.1335; M. Pecina, M. Sikora, E. T. Avery, J. Heffernan, S. Pecina, B. J. Mickey, and J. K. Zubieta, “Striatal Dopamine D2/3 Receptor-Mediated Neurotransmission in Major Depression: Implications for Anhedonia, Anxiety and Treatment Response,” European Neuropsychopharmacology 27, no. 10 (October 2017): 977–986, https://doi.org/10.1016/j.euroneuro.2017.08.427.
1. S. Adler, Sleep Paralysis: Night-Mares, Nocebos, and the Mind-Body Connection (New Brunswick, NJ: Rutgers University Press, 2011).
2. N. Sawamoto, M. Honda, T. Okada, T. Hanakawa, M. Kanda, H. Fukuyama, J. Konishi, and H. Shibasaki, “Expectation of Pain Enhances Responses to Nonpainful Somatosensory Stimulation in the Anterior Cingulate Cortex and Parietal Operculum/Posterior Insula: An Event-Related Functional Magnetic Resonance Imaging Study,” Journal of Neuroscience 20, no. 19 (October 1, 2000): 7438–7445, https://www.ncbi.nlm.nih.gov/pubmed/11007903; T. Koyama, J. G. McHaffie, P. J. Laurienti, and R. C. Coghill, “The Subjective Experience of Pain: Where Expectations Become Reality,” Proceedings of the National Academy of Sciences of the United States of America 102, no. 36 (September 6, 2005): 12950–12955, https://doi.org/10.1073/pnas.0408576102; J. R. Keltner, A. Furst, C. Fan, R. Redfern, B. Inglis, and H. L. Fields, “Isolating the Modulatory Effect of Expectation on Pain Transmission: A Functional Magnetic Resonance Imaging Study,” Journal of Neuroscience 26, no. 16 (April 19, 2006): 4437–4443, https://doi.org/10.1523/JNEUROSCI.4463-05.2006.
3. P. M. Ridker, “The Jupiter Trial: Results, Controversies, and Implications for Prevention,” Circulation: Cardiovascular Quality and Outcomes 2, no. 3 (May 2009): 279–285, https://doi.org/10.1161/CIRCOUTCOMES.109.868299.
4. F. A. Wood, J. P. Howard, J. A. Finegold, A. N. Nowbar, D. M. Thompson, A. D. Arnold, C. A. Rajkumar, et al., “N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects,” New England Journal of Medicine 383, no. 22 (November 26, 2020): 2182–2184, https://doi.org/10.1056/NEJMc2031173.
5. M. Amanzio, L. L. Corazzini, L. Vase, and F. Benedetti, “A Systematic Review of Adverse Events in Placebo Groups of Anti-Migraine Clinical Trials,” Pain 146, no. 3 (December 2009): 261–269, https://doi.org/10.1016/j.pain.2009.07.010; W. Rief, Y. Nestoriuc, A. von Lilienfeld-Toal, I. Dogan, F. Schreiber, S. G. Hofmann, A. J. Barsky, and J. Avorn, “Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials: A Systematic Review and Meta-Analysis,” Drug Safety 32, no. 11 (2009): 1041–1056, https://doi.org/10.2165/11316580-000000000-00000.
6. A. Silvestri, P. Galetta, E. Cerquetani, G. Marazzi, R. Patrizi, M. Fini, and G. M. Rosano, “Report of Erectile Dysfunction after Therapy with Beta-blockers Is Related to Patient Knowledge of Side Effects and Is Reversed by Placebo,” European Heart Journal 24, no. 21 (November 2003): 1928–1932, https://doi.org/10.1016/j.ehj.2003.08.016.
7. T. J. Kaptchuk, J. M. Kelley, L. A. Conboy, R. B. Davis, C. E. Kerr, E. E. Jacobson, I. Kirsch, et al., “Components of Placebo Effect: Randomised Controlled Trial in Patients with Irritable Bowel Syndrome,” British Medical Journal 336, no. 7651 (May 3, 2008): 999–1003, https://doi.org/10.1136/bmj.39524.439618.25.
8. L. C. Howe, J. P. Goyer, and A. J. Crum, “Harnessing the Placebo Effect: Exploring the Influence of Physician Characteristics on Placebo Response,” Health Psychology 36, no. 11 (November 2017): 1074–1082, https://doi.org/10.1037/hea0000499.
9. H. E. Yetman, N. Cox, S. R. Adler, K. T. Hall, and V. E. Stone, “What Do Placebo and Nocebo Effects Have to Do with Health Equity? The Hidden Toll of Nocebo Effects on Racial and Ethnic Minority Patients in Clinical Care,” Frontiers in psychology 12 (2021): 788230. https://doi.org/10.3389/fpsyg.2021.788230.
10. P. Friesen, and C. Blease, “Placebo Effects and Racial and Ethnic Health Disparities: An Unjust and Underexplored Connection,” Journal of Medical Ethics 44, no. 11 (November 2018): 774–781, https://doi.org/10.1136/medethics-2018-104811.
11. E. M. Hooper, L. M. Comstock, J. M. Goodwin, and J. S. Goodwin, “Patient Characteristics That Influence Physician Behavior,” Medical Care 20, no. 6 (June 1982): 630–638, https://doi.org/10.1097/00005650-198206000-00009.
12. W. J. Ferguson and L. M. Candib, “Culture, Language, and the Doctor-Patient Relationship,” Family Medicine 34, no. 5 (May 2002): 353–361, https://www.ncbi.nlm.nih.gov/pubmed/12038717.
13. R. L. Johnson, D. Roter, N. R. Powe, and L. A. Cooper, “Patient Race/Ethnicity and Quality of Patient-Physician Communication during Medical Visits,” American Journal of Public Health 94, no. 12 (December 2004): 2084–2090, https://doi.org/10.2105/ajph.94.12.2084.
14. L. Y. Atlas, “A Social Affective Neuroscience Lens on Placebo Analgesia,” Trends in Cognitive Sciences 25, no. 11 (November 2021): 992–1005, https://doi.org/10.1016/j.tics.2021.07.016.
15. A. W. M. Evers, L. Colloca, C. Blease, J. Gaab, K. B. Jensen, L. Y. Atlas, C. J. Beedie, et al., “What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus,” Psychotherapy and Psychosomatics 90, no. 1 (2021): 49–56, https://doi.org/10.1159/000510738.
16. L. Colloca and A. J. Barsky, “Placebo and Nocebo Effects,” New England Journal of Medicine 382, no. 6 (February 6, 2020): 554–561, https://doi.org/10.1056/NEJMra1907805.
17. D. L. Washington, J. Bowles, S. Saha, C. R. Horowitz, S. Moody-Ayers, A. F. Brown, V. E. Stone, et al., “Transforming Clinical Practice to Eliminate Racial-Ethnic Disparities in Healthcare,” Journal of General Internal Medicine 23, no. 5 (May 2008): 685–691, https://doi.org/10.1007/s11606-007-0481-0.
18. Y. Sciama, “France Brings Back a Phased-Out Drug after Patients Rebel against Its Replacement,” ScienceInsider, September 27, 2017, https://www.science.org/content/article/france-brings-back-phased-out-drug-after-patients-rebel-against-its-replacement.
19. K. Faasse, K., T. Cundy, and K. J. Petrie, “Thyroxine: Anatomy of a Health Scare,” British Medical Journal 339 (December 29 2009): b5613, https://doi.org/10.1136/bmj.b5613.
20. M. Amanzio, J. Howick, M. Bartoli, G. E. Cipriani, and J. Kong, “How Do Nocebo Phenomena Provide a Theoretical Framework for the COVID-19 Pandemic?,” Frontiers in Psychology 11 (2020): 589884, https://doi.org/10.3389/fpsyg.2020.589884.
21. J. W. Haas, F. L. Bender, S. Ballou, J. M. Kelley, M. Wilhelm, F. G. Miller, W. Rief, et al., “Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis,” JAMA Network Open 5, no. 1 (2022): e2143955, https://https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788172.
22. W. S. Chou and A. Budenz, “Considering Emotion in COVID-19 Vaccine Communication: Addressing Vaccine Hesitancy and Fostering Vaccine Confidence,” Health Communication 35, no. 14 (December 2020): 1718–1722, https://doi.org/10.1080/10410236.2020.1838096.
23. “U.S. COVID-19 Vaccine Tracker: See Your State’s Progress,” 2021, https://www.mayoclinic.org/coronavirus-covid-19/vaccine-tracker; “COVID Data Tracker Weekly Review,” Centers for Disease Control and Prevention, 2021, https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html.
24. “COVID-19 19 Tracker,” Reuters, 2021, https://graphics.reuters.com/world-coronavirus-tracker-and-maps/countries-and-territories/portugal/; M. Santora and R. Minder, “In Portugal, There Is Virtually No One Left to Vaccinate,” New York Times, 2021, https://www.nytimes.com/2021/10/01/world/europe/portugal-vaccination-rate.html.
1. R. H. Dworkin, D. C. Turk, N. P. Katz, M. C. Rowbotham, S. Peirce-Sandner, I. Cerny, C. S. Clingman, et al., “Evidence-Based Clinical Trial Design for Chronic Pain Pharmacotherapy: A Blueprint for ACTION,” Pain 152, no. 3 (March 2011): S107–S115, https://doi.org/10.1016/j.pain.2010.11.008; K. Evans, H. Romero, E. L. Spierings, and N. Katz, “The Relation between the Placebo Response, Observed Treatment Effect, and Failure to Meet Primary Endpoint: A Systematic Review of Clinical Trials of Preventative Pharmacological Migraine Treatments,” Cephalalgia 41, no. 2 (February 2021): 247–255, https://doi.org/10.1177/0333102420960020.
2. O. J. Wouters, M. McKee, and J. Luyten, “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009–2018,” Journal of the American Medical Association 323, no. 9 (March 3, 2020): 844–853, https://doi.org/10.1001/jama.2020.1166.
3. S. Pretorius and A. Grignolo, “Phase III Trial Failures: Costly, but Preventable,” Applied Clinical Trials 25, no. 8 (2016), https://www.appliedclinicaltrialsonline.com/view/phase-iii-trial-failures-costly-preventable.
4. “2021 Alzheimer’s Disease Facts and Figures: Race, Ethnicity and Alzheimer’s in America,” Alzheimer’s Association, 2021, https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf.
5. F. Benedetti, C. Arduino, S. Costa, S. Vighetti, L. Tarenzi, I. Rainero, and G. Asteggiano, “Loss of Expectation-Related Mechanisms in Alzheimer’s Disease Makes Analgesic Therapies Less Effective,” Pain 121, no. 1–2 (March 2006): 133–144, https://doi.org/10.1016/j.pain.2005.12.016.
6. J. Lim, L. Wang, N. Best, J. Liu, J. Yuan, F. Yong, L. Zhang, et al., “Reducing Patient Burden in Clinical Trials through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias,” Therapeutic Innovation and Regulatory Science 54, no. 4 (July 2020): 850–860, https://doi.org/10.1007/s43441-019-00014-4; K. Ito and K. Romero, “Placebo Effect in Subjects with Cognitive Impairment,” International Review of Neurobiology 153 (2020): 213–230, https://doi.org/10.1016/bs.irn.2020.03.032.
7. J. Sevigny, P. Chiao, T. Bussiere, P. H. Weinreb, L. Williams, M. Maier, R. Dunstan, et al., “The Antibody Aducanumab Reduces Aβ Plaques in Alzheimer’s Disease,” Nature 537, no. 7618 (September 1, 2016): 50–56, https://doi.org/10.1038/nature19323.
8. R. K. McHugh, S. W. Whitton, A. D. Peckham, J. A. Welge, and M. W. Otto, “Patient Preference for Psychological vs Pharmacologic Treatment of Psychiatric Disorders: A Meta-Analytic Review,” Journal of Clinical Psychiatry 74, no. 6 (June 2013): 595–602, https://doi.org/10.4088/JCP.12r07757.
9. I. Kirsch and G. Sapirstein, “Listening to Prozac but Hearing Placebo: A Meta-Analysis of Antidepressant Medication,” Prevention and Treatment 1, no. 2 (1998), article 2a, https://psycnet.apa.org/record/1999-11094-001.
10. A. Khan, R. M. Leventhal, S. R. Khan, and W. A. Brown, “Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database,” Journal of Clinical Psychopharmacology 22, no. 1 (February 2002): 40–45, https://www.ncbi.nlm.nih.gov/pubmed/11799341.
11. I. Kirsch, B. J. Deacon, T. B. Huedo-Medina, A. Scoboria, T. J. Moore, and B. T. Johnson, “Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration,” PLoS Medicine 5, no. 2 (February 2008): e45, https://doi.org/10.1371/journal.pmed.0050045.
12. E. H. Turner, A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal, “Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy,” New England Journal of Medicine 358, no. 3 (January 17, 2008): 252–260, https://doi.org/10.1056/NEJMsa065779.
13. A. Cipriani, T. A. Furukawa, G. Salanti, A. Chaimani, L. Z. Atkinson, Y. Ogawa, S. Leucht, et al., “Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults with Major Depressive Disorder: A Systematic Review and Network Meta-Analysis,” Lancet 391, no. 10128 (April 7, 2018): 1357–1366, https://doi.org/10.1016/S0140-6736(17)32802-7.
14. M. Stone, S. N. Kalaria, K. Richardville, and B. J. Miller, “Components and Trends in Treatment Effects in Randomized Placebo-Controlled Trials in Major Depressive Disorder from 1979–2016” (paper presented at the American Society of Clinical Psychopharmacology Annual Conference, May 2018), https://www.researchgate.net/publication/334806796_Components_and_trends_in_treatment_effects_in_randomized_placebo-controlled_trials_in_major_depressive_disorder_from_1979-2016.
15. K. T. Hall, L. Vase, D. K. Tobias, H. T. Dashti, J. Vollert, T. J. Kaptchuk, and N. R. Cook, “Historical Controls in Randomized Clinical Trials: Opportunities and Challenges,” Clinical Pharmacology and Therapeutics (June 30, 2020), https://doi.org/10.1002/cpt.1970.
16. J. R. Curtis, J. C. Larson, E. Delzell, M. A. Brookhart, S. M. Cadarette, R. Chlebowski, S. Judd, et al., “Placebo Adherence, Clinical Outcomes, and Mortality in the Women’s Health Initiative Randomized Hormone Therapy Trials,” Medical Care 49, no. 5 (May 2011): 427–435, https://doi.org/10.1097/MLR.0b013e318207ed9e.
17. T. R. Zijp, D. J. Touw, and J. F. M. van Boven, “User Acceptability and Technical Robustness Evaluation of a Novel Smart Pill Bottle Prototype Designed to Support Medication Adherence,” Patient Preference and Adherence 14 (2020): 625–634, https://doi.org/10.2147/PPA.S240443.
18. S. Lee, J. R. Walker, L. Jakul, and K. Sexton, “Does Elimination of Placebo Responders in a Placebo Run-in Increase the Treatment Effect in Randomized Clinical Trials? A Meta-Analytic Evaluation,” Depression and Anxiety 19, no. 1 (2004): 10–19, https://doi.org/10.1002/da.10134; T. A. Hulshof, S. U. Zuidema, C. C. Gispen-de Wied, and H. J. Luijendijk, “Run-in Periods and Clinical Outcomes of Antipsychotics in Dementia: A Meta-Epidemiological Study of Placebo-Controlled Trials,” Pharmacoepidemiology and Drug Safety 29, no. 2 (February 2020): 125–133, https://doi.org/10.1002/pds.4903.
19. I. Chalmers and M. Clarke, “Commentary: The 1944 Patulin Trial: The First Properly Controlled Multicentre Trial Conducted under the Aegis of the British Medical Research Council,” International Journal of Epidemiology 33, no. 2 (April 2004): 253–260, https://doi.org/10.1093/ije/dyh162.
20. Chalmers and Clarke, “Commentary.”
1. D. C. Sabiston and A. Blalock, “Experimental Ligation of the Internal Mammary Artery and Its Effect on Coronary Occlusion,” Surgery 43, no. 6 (June 1958): 906–912, https://www.ncbi.nlm.nih.gov/pubmed/13543665.
2. L. A. Cobb, G. I. Thomas, D. H. Dillard, K. A. Merendino, and R. A. Bruce, “An Evaluation of Internal-Mammary-Artery Ligation by a Double-Blind Technic,” New England Journal of Medicine 260, no. 22 (May 28, 1959): 1115–1118, https://doi.org/10.1056/NEJM195905282602204.
3. E. G. Dimond, C. F. Kittle, and J. E. Crockett, “Comparison of Internal Mammary Artery Ligation and Sham Operation for Angina Pectoris,” American Journal of Cardiology 5 (April 1960): 483–486, https://doi.org/10.1016/0002-9149(60)90105-3.
4. H. K. Beecher, “Surgery as Placebo: A Quantitative Study of Bias,” Journal of the American Medical Association 176 (July 1, 1961): 1102–1107, https://doi.org/10.1001/jama.1961.63040260007008.
5. H. K. Beecher, “Surgery as Placebo: A Quantitative Study of Bias,” Journal of the American Medical Association 176 (July 1, 1961): 1102–1107, https://doi.org/10.1001/jama.1961.63040260007008.
6. Beecher, “Surgery as Placebo.”
7. C. Linde, F. Gadler, L. Kappenberger, and L. Ryden, “Placebo Effect of Pacemaker Implantation in Obstructive Hypertrophic Cardiomyopathy. Pic Study Group. Pacing in Cardiomyopathy,” American Journal of Cardiology 83, no. 6 (March 15, 1999): 903–907, https://doi.org/10.1016/s0002-9149(98)01065-0.
8. C. R. Freed, P. E. Greene, R. E. Breeze, W. Y. Tsai, W. DuMouchel, R. Kao, S. Dillon, et al., “Transplantation of Embryonic Dopamine Neurons for Severe Parkinson’s Disease,” New England Journal of Medicine 344, no. 10 (March 8, 2001): 710–719, https://doi.org/10.1056/NEJM200103083441002.
9. L. Wall, M. Hinwood, D. Lang, A. Smith, S. Bunzli, P. Clarke, P. F. M. Choong, et al., “Attitudes of Patients and Surgeons towards Sham Surgery Trials: A Protocol for a Scoping Review of Attributes to Inform a Discrete Choice Experiment,” British Medical Journal Open 10, no. 3 (March 10, 2020): e035870, https://doi.org/10.1136/bmjopen-2019-035870.
10. J. B. Moseley, K. O’Malley, N. J. Petersen, T. J. Menke, B. A. Brody, D. H. Kuykendall, J. C. Hollingsworth, et al., “A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee,” New England Journal of Medicine 347, no. 2 (July 11, 2002): 81–88, https://doi.org/10.1056/NEJMoa013259.
11. T. L. N. Jarvinen and G. H. Guyatt, “Arthroscopic Surgery for Knee Pain: A Highly Questionable Practice without Supporting Evidence of Even Moderate Quality,” British Journal of Sports Medicine 50, no. 23 (December 2016): 1426–1427, https://doi.org/10.1136/bmj.i3934rep.
12. H. C. Patel, C. Hayward, B. A. Ozdemir, S. D. Rosen, H. Krum, A. R. Lyon, D. P. Francis, and C. di Mario, “Magnitude of Blood Pressure Reduction in the Placebo Arms of Modern Hypertension Trials: Implications for Trials of Renal Denervation,” Hypertension 65, no. 2 (February 2015): 401–406, https://doi.org/10.1161/HYPERTENSIONAHA.114.04640.
13. A. Persu, F. Maes, J. Renkin, and A. Pathak, “Renal Denervation in Hypertensive Patients: Back to Anatomy?,” Hypertension 76, no. 4 (October 2020): 1084–1086, https://doi.org/10.1161/HYPERTENSIONAHA.120.15834.
14. K. Wartolowska, A. Judge, S. Hopewell, G. S. Collins, B. J. Dean, I. Rombach, D. Brindley, et al., “Use of Placebo Controls in the Evaluation of Surgery: Systematic Review,” British Medical Journal 348 (May 21, 2014): g3253, https://doi.org/10.1136/bmj.g3253.
15. D. L. Bhatt, D. E. Kandzari, W. W. O’Neill, R. D’Agostino, J. M. Flack, B. T. Katzen, M. B. Leon, et al., “A Controlled Trial of Renal Denervation for Resistant Hypertension,” New England Journal of Medicine 370, no. 15 (April 10, 2014): 1393–1401, https://doi.org/10.1056/NEJMoa1402670.
16. Jarvinen and Guyatt, “Arthroscopic Surgery for Knee Pain”; A. Carr, “Arthroscopic Surgery for Degenerative Knee,” British Medical Journal 350 (2015): h2983, https://doi.org/10.1136/bmj.h2983.
1. A. Kern, C. Kramm, C. M. Witt, and J. Barth, “The Influence of Personality Traits on the Placebo/Nocebo Response: A Systematic Review,” Journal of Psychosomatic Research 128 (January 2020): 109866, https://doi.org/10.1016/j.jpsychores.2019.109866.
2. A. L. Geers, J. A. Wellman, S. L. Fowler, S. G. Helfer, and C. R. France, “Dispositional Optimism Predicts Placebo Analgesia,” Journal of Pain 11, no. 11 (November 2010): 1165–1171, https://doi.org/10.1016/j.jpain.2010.02.014.
3. A. L. Geers, S. G. Helfer, K. Kosbab, P. E. Weiland, and S. J. Landry, “Reconsidering the Role of Personality in Placebo Effects: Dispositional Optimism, Situational Expectations, and the Placebo Response,” Journal of Psychosomatic Research 58, no. 2 (February 2005): 121–127, https://www.ncbi.nlm.nih.gov/pubmed/15820839.
4. J. M. Kelley, A. J. Lembo, J. S. Ablon, J. J. Villanueva, L. A. Conboy, R. Levy, C. D. Marci, et al., “Patient and Practitioner Influences on the Placebo Effect in Irritable Bowel Syndrome,” Psychosomatic Medicine 71, no. 7 (September 2009): 789–797, https://doi.org/10.1097/PSY.0b013e3181acee12.
5. P. Tetreault, A. Mansour, E. Vachon-Presseau, T. J. Schnitzer, A. V. Apkarian, and M. N. Baliki, “Brain Connectivity Predicts Placebo Response across Chronic Pain Clinical Trials,” PLoS Biology 14, no. 10 (October 2016): e1002570, https://doi.org/10.1371/journal.pbio.1002570.
6. E. Vachon-Presseau, S. E. Berger, T. B. Abdullah, L. Huang, G. A. Cecchi, J. W. Griffith, T. J. Schnitzer, and A. V. Apkarian, “Brain and Psychological Determinants of Placebo Pill Response in Chronic Pain Patients,” Nature Communications 9, no. 1 (September 12, 2018): article 3397, https://doi.org/10.1038/s41467-018-05859-1.
7. S. Zilcha-Mano, S. P. Roose, P. J. Brown, and B. R. Rutherford, “A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials,” American Journal of Geriatric Psychiatry 26, no. 6 (June 2018): 669–677, https://doi.org/10.1016/j.jagp.2018.01.001.
8. P. A. Nakonezny, T. L. Mayes, M. J. Byerly, and G. J. Emslie, “Predicting Placebo Response in Adolescents with Major Depressive Disorder: The Adolescent Placebo Impact Composite Score (APICS),” Journal of Psychiatric Research 68 (September 2015): 346–353, https://doi.org/10.1016/j.jpsychires.2015.05.003.
9. J. K. Park, S. H. Ahn, K. Shin, Y. J. Lee, Y. W. Song, and E. B. Lee, “Predictors of a Placebo Response in Patients with Hand Osteoarthritis: Post-Hoc Analysis of Two Randomized Controlled Trials,” BMC Musculoskeletal Disorders 22, no. 1 (March 4, 2021): article 244, https://doi.org/10.1186/s12891-021-04089-9; J. Vollert, N. R. Cook, T. J. Kaptchuk, S. T. Sehra, D. K. Tobias, and K. T. Hall, “Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials,” Journal of the American Medical Association Network Open 3, no. 9 (September 1, 2020): e2013196, https://doi.org/10.1001/jamanetworkopen.2020.13196.
10. J. Chen, B. K. Lipska, N. Halim, Q. D. Ma, M. Matsumoto, S. Melhem, B. S. Kolachana, et al., “Functional Analysis of Genetic Variation in Catechol-O-methyltransferase (COMT): Effects on mRNA, Protein, and Enzyme Activity in Postmortem Human Brain,” American Journal of Human Genetics 75, no. 5 (November 2004): 807–821, https://doi.org/10.1086/425589.
11. K. T. Hall, A. J. Lembo, I. Kirsch, D. C. Ziogas, J. Douaiher, K. B. Jensen, L. A. Conboy, et al., “Catechol-O-methyltransferase val158met Polymorphism Predicts Placebo Effect in Irritable Bowel Syndrome,” PLoS One 7, no. 10 (2012): e48135, https://doi.org/10.1371/journal.pone.0048135.
12. R.-S. Wang, A. J. Lembo, T. J. Kaptchuk, V. Cheng, J. Nee, J. Iturrino, M. Rao, J. Loscalzo, J. A. Silvester, and K. T. Hall, “Genomic Effects Associated with Response to Placebo Treatment in a Randomized Trial of Irritable Bowel Syndrome,” Frontiers in Pain Research (2022), https://www.frontiersin.org/article/10.3389/fpain.2021.775386.
13. G. D. Slade, R. B. Fillingim, R. Ohrbach, H. Hadgraft, J. Willis, S. J. Arbes Jr., and I. E. Tchivileva, “COMT Genotype and Efficacy of Propranolol for TMD Pain: A Randomized Trial,” Journal of Dental Research 100, no. 2 (February 2021): 163–170, https://doi.org/10.1177/0022034520962733; K. T. Hall, J. Kossowsky, T. F. Oberlander, T. J. Kaptchuk, J. P. Saul, V. B. Wyller, E. Fagermoen, et al., “Genetic Variation in Catechol-O-methyltransferase Modifies Effects of Clonidine Treatment in Chronic Fatigue Syndrome,” Pharmacogenomics Journal 16, no. 5 (October 2016): 454–460, https://doi.org/10.1038/tpj.2016.53; K. T. Hall, C. P. Nelson, R. B. Davis, J. E. Buring, I. Kirsch, M. A. Mittleman, J. Loscalzo, et al., “Polymorphisms in Catechol-O-methyltransferase Modify Treatment Effects of Aspirin on Risk of Cardiovascular Disease,” Arteriosclerosis, Thrombosis, and Vascular Biology 34, no. 9 (September 2014): 2160–2167, https://doi.org/10.1161/ATVBAHA.114.303845; K. T. Hall, J. E. Buring, K. J. Mukamal, M. Vinayaga Moorthy, P. M. Wayne, T. J. Kaptchuk, E. M. Battinelli, et al., “COMT and Alpha-Tocopherol Effects in Cancer Prevention: Gene-Supplement Interactions in Two Randomized Clinical Trials,” Journal of the National Cancer Institute 111, no. 7 (July 1, 2019): 684–694, https://doi.org/10.1093/jnci/djy204.
14. R. S. Wang, K. T. Hall, F. Giulianini, D. Passow, T. J. Kaptchuk, and J. Loscalzo, “Network Analysis of the Genomic Basis of the Placebo Effect,” JCI Insight 2, no. 11 (June 2, 2017), https://doi.org/10.1172/jci.insight.93911.
1. C. P. Skipper, K. A. Pastick, N. W. Engen, A. S. Bangdiwala, M. Abassi, S. M. Lofgren, D. A. Williams, et al., “Hydroxychloroquine in Nonhospitalized Adults with Early COVID-19: A Randomized Trial,” Annals of Internal Medicine 173, no. 8 (October 20, 2020): 623–631, https://doi.org/10.7326/M20-4207.
2. L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, et al., “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,” New England Journal of Medicine 384, no. 5 (February 4, 2021): 403–416, https://doi.org/10.1056/NEJMoa2035389; J. H. Beigel, K. M. Tomashek, L. E. Dodd, A. K. Mehta, B. S. Zingman, A. C. Kalil, E. Hohmann, et al., “Remdesivir for the Treatment of Covid-19—Final Report,” New England Journal of Medicine 383, no. 19 (November 5, 2020): 1813–1826, https://doi.org/10.1056/NEJMoa2007764.
3. J. Braga-Simoes, P. S. Costa, and J. Yaphe, “Placebo Prescription and Empathy of the Physician: A Cross-Sectional Study,” European Journal of General Practice 23, no. 1 (December 2017): 98–104, https://doi.org/10.1080/13814788.2017.1291625; M. Fassler, K. Meissner, A. Schneider, and K. Linde, “Frequency and Circumstances of Placebo Use in Clinical Practice—a Systematic Review of Empirical Studies,” BMC Medicine 8 (February 23, 2010): article 15, https://doi.org/10.1186/1741-7015-8-15.
4. C. S. Harris, N. K. Campbell, and A. Raz, “Placebo Trends across the Border: US versus Canada,” PLoS One 10, no. 11 (2015): e0142804, https://doi.org/10.1371/journal.pone.0142804.
5. P. C. Scriba, “Placeboaspekte der Arzt-Patienten-Beziehung. Ubersicht” [Placebo and the relationship between doctors and patients. Overview]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 55, no. 9 (September 2012): 1113–1117, https://doi.org/10.1007/s00103-012-1526-z.
6. T. J. Kaptchuk and F. G. Miller,” “Open Label Placebo: Can Honestly Prescribed Placebos Evoke Meaningful Therapeutic Benefits?,” British Medical Journal 363 (October 2, 2018): k3889, https://doi.org/10.1136/bmj.k3889.
7. C. Carvalho, J. M. Caetano, L. Cunha, P. Rebouta, T. J. Kaptchuk, and I. Kirsch, “Open-Label Placebo Treatment in Chronic Low Back Pain: A Randomized Controlled Trial,” Pain 157, no. 12 (December 2016): 2766–2772, https://doi.org/10.1097/j.pain.0000000000000700; T. W. Hoenemeyer, T. J. Kaptchuk, T. S. Mehta, and K. R. Fontaine, “Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial,” Scientific Reports 8, no. 1 (February 9, 2018): article 2784, https://doi.org/10.1038/s41598-018-20993-y; E. S. Zhou, K. T. Hall, A. L. Michaud, J. E. Blackmon, A. H. Partridge, and C. J. Recklitis, “Open-Label Placebo Reduces Fatigue in Cancer Survivors: A Randomized Trial,” Support Care Cancer 27 (October 10, 2018): 2179–2187, https://doi.org/10.1007/s00520-018-4477-6; M. Schaefer, R. Harke, and C. Denke, “Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial,” Psychotherapy and Psychosomatics 85, no. 6 (2016): 373–374, https://doi.org/10.1159/000447242; M. von Wernsdorff, M. L. Loef, B. Tuschen-Caffier, and S. Schmidt, “Effects of Open-Label Placebos in Clinical Trials: A Systematic Review and Meta-Analysis,” Scientific Reports 11, no. 1 (February 16, 2021): article 3855, https://doi.org/10.1038/s41598-021-83148-6.
8. G. Ongaro and T. J. Kaptchuk, “Symptom Perception, Placebo Effects, and the Bayesian Brain,” Pain 160, no. 1 (January 2019): 1–4, https://doi.org/10.1097/j.pain.0000000000001367.
9. S. H. Kollins, D. J. DeLoss, E. Canadas, J. Lutz, R. L. Findling, R. S. E. Keefe, J. N. Epstein, et al., “A Novel Digital Intervention for Actively Reducing Severity of Paediatric ADHD (STARS-ADHD): A Randomised Controlled Trial,” Lancet Digital Health 2, no. 4 (April 2020): e168–e178, https://doi.org/10.1016/S2589-7500(20)30017-0.
10. P. Cipresso, I. A. C. Giglioli, M. A. Raya, and G. Riva, “The Past, Present, and Future of Virtual and Augmented Reality Research: A Network and Cluster Analysis of the Literature,” Frontiers in Psychology 9 (2018): 2086, https://doi.org/10.3389/fpsyg.2018.02086.
11. M. J. Park, D. J. Kim, U. Lee, E. J. Na, and H. J. Jeon, “A Literature Overview of Virtual Reality (VR) in Treatment of Psychiatric Disorders: Recent Advances and Limitations,” Frontiers in Psychiatry 10 (2019): 505, https://doi.org/10.3389/fpsyt.2019.00505; Z. Trost, C. France, M. Anam, and C. Shum, “Virtual Reality Approaches to Pain: Toward a State of the Science,” Pain 162, no. 2 (February 1, 2021): 325–331, https://doi.org/10.1097/j.pain.0000000000002060.
12. J. R. Forsyth, H. Chase, N. W. Roberts, L. C. Armitage, and A. J. Farmer, “Application of the National Institute for Health and Care Excellence Evidence Standards Framework for Digital Health Technologies in Assessing Mobile-Delivered Technologies for the Self-Management of Type 2 Diabetes Mellitus: Scoping Review,” JMIR Diabetes 6, no. 1 (February 16, 2021): e23687, https://doi.org/10.2196/23687.